Historical Valuation
ImmuCell Corp (ICCC) is now in the Fair zone, suggesting that its current forward PS ratio of 3.22 is considered Fairly compared with the five-year average of -60.39. The fair price of ImmuCell Corp (ICCC) is between 4.63 to 7.53 according to relative valuation methord.
Relative Value
Fair Zone
4.63-7.53
Current Price：6.55
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
ImmuCell Corp (ICCC) has a current Price-to-Book (P/B) ratio of 1.80. Compared to its 3-year average P/B ratio of 1.58 , the current P/B ratio is approximately 13.93% higher. Relative to its 5-year average P/B ratio of 1.80, the current P/B ratio is about -0.26% higher. ImmuCell Corp (ICCC) has a Forward Free Cash Flow (FCF) yield of approximately 1.34%. Compared to its 3-year average FCF yield of -8.72%, the current FCF yield is approximately -115.32% lower. Relative to its 5-year average FCF yield of -6.57% , the current FCF yield is about -120.33% lower.
P/B
Median3y
1.58
Median5y
1.80
FCF Yield
Median3y
-8.72
Median5y
-6.57
Competitors Valuation Multiple
AI Analysis for ICCC
The average P/S ratio for ICCC competitors is 1.95, providing a benchmark for relative valuation. ImmuCell Corp Corp (ICCC.O) exhibits a P/S ratio of 3.22, which is 65.21% above the industry average. Given its robust revenue growth of -8.41%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ICCC
1Y
3Y
5Y
Market capitalization of ICCC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ICCC in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ICCC currently overvalued or undervalued?
ImmuCell Corp (ICCC) is now in the Fair zone, suggesting that its current forward PS ratio of 3.22 is considered Fairly compared with the five-year average of -60.39. The fair price of ImmuCell Corp (ICCC) is between 4.63 to 7.53 according to relative valuation methord.
What is ImmuCell Corp (ICCC) fair value?
ICCC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of ImmuCell Corp (ICCC) is between 4.63 to 7.53 according to relative valuation methord.
How does ICCC's valuation metrics compare to the industry average?
The average P/S ratio for ICCC's competitors is 1.95, providing a benchmark for relative valuation. ImmuCell Corp Corp (ICCC) exhibits a P/S ratio of 3.22, which is 65.21% above the industry average. Given its robust revenue growth of -8.41%, this premium appears unsustainable.
What is the current P/B ratio for ImmuCell Corp (ICCC) as of Jan 09 2026?
As of Jan 09 2026, ImmuCell Corp (ICCC) has a P/B ratio of 1.80. This indicates that the market values ICCC at 1.80 times its book value.
What is the current FCF Yield for ImmuCell Corp (ICCC) as of Jan 09 2026?
As of Jan 09 2026, ImmuCell Corp (ICCC) has a FCF Yield of 1.34%. This means that for every dollar of ImmuCell Corp’s market capitalization, the company generates 1.34 cents in free cash flow.
What is the current Forward P/E ratio for ImmuCell Corp (ICCC) as of Jan 09 2026?
As of Jan 09 2026, ImmuCell Corp (ICCC) has a Forward P/E ratio of -53.82. This means the market is willing to pay $-53.82 for every dollar of ImmuCell Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for ImmuCell Corp (ICCC) as of Jan 09 2026?
As of Jan 09 2026, ImmuCell Corp (ICCC) has a Forward P/S ratio of 3.22. This means the market is valuing ICCC at $3.22 for every dollar of expected revenue over the next 12 months.